key: cord-0810542-j6ve8f7i
authors: Fouda, M.; Kuriakose, V.
title: P168 Assessing the Impact of the COVID-19 outbreak on the oncological practice regarding metastatic breast cancer patients treated with CDK4/6 inhibitors
date: 2021-04-30
journal: The Breast
DOI: 10.1016/s0960-9776(21)00256-3
sha: a11de0a722e0bc09d0ee779879347fb8708e2a87
doc_id: 810542
cord_uid: j6ve8f7i

nan

Goals: On April 26th 1986, the Chernobyl accident led to a large release of radionuclides, and subsequent deposition of radionuclides over a large region, particularly in Russia, Ukraine and East Europe. Previous work has demonstrated that in the immediate regions surrounding Chernobyl, women who were younger at the time of exposure are more prone to breast cancer approximately 10 years after exposure (with women in the most contaminated regions being at the highest risk). We postulate, there maybe delayed effects leading to increased breast cancer incidence related to irradiation in earlier life or in maternal life. Furthermore, we believe these breast cancers to form a distinct subcategory, often being resistant to standard chemotherapeutic agents used. Methods: We performed a retrospective analysis of all patients diagnosed with new breast cancer in 2018 at Barts Health NHS Trust. Russian, Ukrainian and Eastern European female patients who would have been aged between 0 to 15 at the time of the Chernobyl accident were identified. Data was collected on tumour characteristics, response to treatment and presence of metastatic disease. Results: 22 patients were identified who presented with breast cancer, 1 patient was excluded as she was found to be BRCA1 positive. Age range of patients was 28-47 years old at time of diagnosis (date of birth year range 1973-1992). 18% of patients of patients had metastatic disease at presentation, and of those commencing neoadjuvant chemotherapy 14% had a poor response. Size of tumour at presentation ranged from 8 to 60 mm, with grade 2/3 invasive cancer in 95% of patients. 1 patient had spindle cell sarcoma. Conclusion(s): We show that young women who would have been exposed to residual radionuclides in the years following 1986, often present with advanced stage breast cancer. There is insufficient evidence within this dataset, to confirm whether this should be classified a distinct subtype of breast cancer. We speculate this is due to residual radiation effects, however would need to conduct a further study including matched paired analysis to non-Eastern European patients to confirm these findings. Conflict of Interest: No significant relationships.

A multi-functional portable system for diagnosing breast cancer from ex-vivo biopsy tissues U.M. Pal 1 , V. Kurpad 2 *, H.J. Pandya# ,1 . 1 Department of Electronic Systems Engineering, Indian Institute of Science, Bangalore, India; 2 Surgical Oncology, Sri Shankara Cancer Hospital, Bangalore, India # Corresponding author, email: hjpandya@iisc.ac.in Goals: Develop a portable system to delineate cancer from normal breast biopsy tissues (N = 5) based on optical, ultrasound, and thermal properties. Methods: The tool quantifies optical, ultrasound, and thermal properties to distinguish between the cancerous and normal breast biopsy tissues. The optical measurements involve a double integrating sphere to quantify the absorption and scattering coefficient. The ultrasound attenuation coefficient was quantified using a piezoelectric transducer, while the thermal properties of the tissue were quantified using the IR thermal imaging camera. Results: A higher scattering coefficient was observed in cancerous tissue compared to normal tissues. Acoustic attenuation coefficient was observed to be higher in cancerous tissue compared to the normal tissues. Thermal conductivity for the normal tissue was observed to be higher compared to the cancerous tissues.

The preliminary results show that the optical, ultrasound and thermal properties of cancer tissues are different from normal tissues. We envision that this study will enable developing non-invasive breast cancer diagnostic tool. Conflict of Interest: No significant relationships.

Assessing the Impact of the COVID-19 outbreak on the oncological practice regarding metastatic breast cancer patients treated with CDK4/6 inhibitors M. Fouda 1 *, V. Kuriakose 2 . 1 Medical Oncology, Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom; 2 Oncology, Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom Goals: During the COVID-19 global pandemic, the cancer management faces many challenges. The ESMO recommended the use of oral targeted agents (CDK4/6) in ER+, metastatic BC must be weighed against the increased risk of adverse events and the dose reductions can minimize treatment-related toxicities (1). This study had been conducted in our trust to evaluate the adoption of the new guidelines for metastatic breast cancer patients who had been treated with CDK4/6 inhibitors and how the COVID19 pandemic has changed the practice and how far the patients been affected. Methods: Forty five patients with metastatic breast cancer during the period from 1st June 2019 to 30 th June 2020 were retrospectively enrolled in the study. Special consideration for the toxicities recorded during the pandemic. Toxicities assessed including fatigue, dirrhea, sepsis, neutropenia, leucopenia, thrombocytopenia, nausea & vomiting. Grades of toxicity were recorded. Options for treatment break, dose reduction, change to 3 monthly prescription were offered. Results: The female patients constitute 95.6%. (11) patients aged above 75 years old were enrolled in the study. Twenty nine (29) patients were on Palbociclib while (16) patients were on Abemaciclib. It is worthy to mention that none of those patients tested positive for Covid -19 during that period. (15) patients had started the treatment during the pandemic from 01/03/2020 to 30/06/2020, (3) of them aged above 75 years old. The following outcomes were shown: 15 Patients had dose reduction (33.3%).6 Patients (13.3%) had treatment break during COVID pandemic. 8 Patients (17.8%) had progressed. 4 Patients (8.9%) changed to 3 monthly prescription. Dose reduction due to toxicities was reported in (40.5%) of cases. (7) Patients (15.6%) had toxicity required admission. 26 Patients (57.8%) continued the treatment without significant toxicities (57.8%). The main toxicities reported with Palbociclib were dirrhea, sepsis, AKI & fatigue while dirrhea was the main toxicity reported with Abemaciclib. A total of (5) patients had severe events and died but non of them was Covid-19 related death. Conclusion(s): The use of oral targeted agents (CDK4/6 inhibitors) in ER+, metastatic BC must be weighed against the increased risk of adverse events. CDK4/6 inhibitors is safe to be given during COVID-19 pandemic, we recommend to continue it in case of second wave of COVID -19. The dose reduction does not affect their efficacy. Conflict of Interest: No significant relationships.

Breast cancer surgery in COVID19 outbreak: the role of therapeutic mammoplasty E. Sfakianakis 1 *, P. Tan 1 , F. Irakleidis 1 . 1 Department of Breast Surgery, Royal Free Hospital, NHS Trust, London, United Kingdom Goals: There is no doubt, that Severe Acute Respiratory Syndrome Coronavirus-2 and it's associated disease (COVID19) has been quite challenging not only for all Health Systems worldwide, but also for all medical professionals, particularly those dealing with cancer patients. There has been a rearrangement of healthcare resources, so that the health systems to be able to deal with the high volume of covid19 patients and the required facilities for their treatment. As a result, routine treatment pathways have been modified. Surgical management of breast cancer patients could not be exempted from treatment pathway modification in the covid19 outbreak era. Main goal is to reduce hospital stay and minimizing the risk for complications and consequently hospital visits, facilitating at the same time oncologic efficiency. Aim of this study is apart from comparing breast surgery cases in two consecutive years, to evaluate the efficacy of therapeutic mammoplasty in breast cancer patients in Covid Outbreak era. Methods: We compared all the breast cases done by a Consultant Oncoplastic Breast Surgeon during covid19 outbreak from March until June in 2020 to the cases done during the same period of time in 2019. Parametres like tumor characteristics, hospital stay, complications, oncologic efficacy, and cosmetic outcome were evaluated. Results: As seen in the Table 1 , all breast cases during Covid19 outbreak were cancer cases, without any reconstruction or surgery for benign breast diseases. The number of cases in total was slightly smaller during the outbreak, compared to ones in 2019. As anticipated, there was no reconstruction or benign cases surgery during Covid19 in compliance with Association of Breast Surgery recommendations and regional/national guidelines during Covid19 outbreak. In terms of Wide Local Excisions all of our cases underwent therapeutic mammoplasties, mainly with Modified Round Block technique. Tumor characteristics can been seen in Table 2 . Surgical outcomes are seen in Table 3 . Goals: To review the tolerance, complications and efficacy of USguided cryoablation in breast cancer (BC) in elderly patients who refuse or are not candidates for surgery. Methods: A retrospective study of the 27 BC (between 60-5 mm, mean 22 mm) treated in our hospital by US-guide cryoablation between March 2019 and June 2020, was carried out in 25 consecutive patients aged between 80 and 94 years (mean 85). The indications reported in the literature were extended to BC larger than 30 mm and the distance to the skin or the pectoral muscle was not considered. US control and BAG were performed 2-3 months after the procedure to assess the effectiveness of the treatment. Successive cryoablations were performed in patients with residual BC until local control was achieved. In patients without residual BC, US control were performed every 6 months. The procedure was performed under local anesthesia (1% lidocaine). The type and number of needles necessary to achieve a cryoablation volume that

Seroma:1 Haematoma:-Wound Infection:1 Wound Dehiscence:--Excellent:11 Good:6 Fair:3 Poor

Seroma: 1 Haematoma:1 Wound Infection:-Wound Dehiscence:-1 Excellent:7 Good:4 Fair:2 Poor

Conclusion(s): In view of Covid19 outbreak, surgical approach to breast cancer patients should ensure oncologic efficiency and minimize exposure to hospital environment. As our data demonstrate, therapeutic mammoplasty is a safe and oncologically efficient approach for breast cancer patients, with minimum complication rates and high satisfaction rates in terms of cosmesis. Therefore, even in challenging pandemic times we are, it can be safely performed by trained Oncoplastic Surgeons

Ultrasound-guided cryoablation as substitute for surgery in elderly patients with non resected breast cancer: pilot study with medium-term outcomes